Low-Dose combo aims to tame bone marrow cancers with fewer side effects
NCT ID NCT05184842
First seen Jan 06, 2026 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This phase 2 trial tests a low-dose weekly schedule of two drugs, decitabine and venetoclax, in people with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), or chronic myelomonocytic leukemia (CMML). The goal is to see if this gentler approach reduces treatment delays and side effects while still controlling the cancer. About 91 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10467, United States
Contact Phone: •••-•••-••••
-
University of California Davis Health (UC Davis Health)
RECRUITINGSacramento, California, 95817, United States
-
White Plains Hospital
RECRUITINGWhite Plains, New York, 10601, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Decitabine and Venetoclax
What this could lead to
If this works, it could offer a gentler treatment option for bone marrow cancers with fewer side effects.
What could go wrong
This is a small, early-phase trial (91 people) focused on tolerability, not yet proven to improve survival or remission rates. The low dose may also be less effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.